Rankings
▼
Calendar
▼
BTAI FY 2015 Earnings Report — BioXcel Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
BioXcel Therapeutics, Inc.
BTAI
FY 2015 Earnings
Reported December 29, 2015
Quarter Comparison
Revenue
Operating Income
EPS (Diluted)
Free Cash Flow
Metric
FY 2015
Prior Q
FY 2014
QoQ Change
YoY Change
Revenue
$0
—
—
—
—
Op. Income
-$636.0K
—
—
—
—
EPS (Diluted)
$-0.64
—
—
—
—
Free Cash Flow
-$281.0K
—
—
—
—
marketcaparena.com
Income Statement
Item
Amount
REVENUE
$0
Cost of Revenue
$0
GROSS PROFIT
$0
R&D Expenses
$233.0K
Selling & Marketing
$0
General & Administrative
$0
SG&A Expenses
$403.0K
Other Expenses
$0
Operating Expenses
$636.0K
Cost & Expenses
$636.0K
OPERATING INCOME
-$636.0K
Interest Income
$0
Interest Expense
$0
Other Income/Expenses
$0
INCOME BEFORE TAX
-$636.0K
Income Tax Expense
$0
Net Income from Continuing Ops
-$636.0K
Net Income from Discontinued Ops
$0
Other Adjustments
$0
NET INCOME
-$636.0K
Net Income Deductions
$0
BOTTOM LINE NET INCOME
-$636.0K
D&A
$0
EBIT
-$636.0K
EBITDA
-$636.0K
EPS
-$1
EPS Diluted
-$1
marketcaparena.com
Cash Flow Statement
Item
Amount
Net Income
-$636.0K
Depreciation & Amortization
$0
Stock-Based Compensation
$0
Deferred Income Tax
$0
Other Non-Cash Items
$182.0K
Change in Working Capital
$174.0K
OPERATING CASH FLOW
-$280.0K
Capital Expenditure
-$1.0K
Acquisitions (Net)
$0
Purchases of Investments
$0
Sales/Maturities of Investments
$0
Other Investing Activities
$0
NET CASH FROM INVESTING
-$1.0K
Net Debt Issuance
$0
Common Stock Repurchased
$0
Common Dividends Paid
$0
Other Financing Activities
$281.0K
NET CASH FROM FINANCING
$281.0K
FREE CASH FLOW
-$281.0K
Net Change in Cash
$0
marketcaparena.com
← FY 2016
BTAI Overview